Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 16/20 | 0.69 |
| ▸ | HTR1B | P28222 | 13/20 | 0.69 |
| ▸ | HTR1F | P30939 | 11/20 | 0.69 |
| ▸ | HTR1A | P08908 | 9/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR1E | P28566 | 1/20 | 0.52 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5906351 | 0.86 | HTR1D (0.65) | HTR1DHTR1BHTR1FHTR1ACHRM2 | |
| SCHEMBL5309846 | 0.86 | HTR1D (0.52) | HTR1DHTR1BHTR1FHTR1A | |
| SCHEMBL6911508 | 0.81 | HTR1D (1.00) | HTR1DHTR1BHTR1FHTR1ACHRM2 | |
| SCHEMBL8149484 | 0.81 | TP53 (0.48) | HTR1DHTR1BHTR1FHTR1A | |
| SCHEMBL10395245 | 0.80 | DYRK1A (0.47) | HTR1DHTR1BHTR1FHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL8604274 | 0.80 | HTR1D (0.98) | HTR1DHTR1BHTR1FHTR1ACHRM2 | |
| SCHEMBL18561355 | 0.78 | GSK3B (0.46) | HTR1DHTR1BHTR1FHTR1A | |
| SCHEMBL28781688 | 0.77 | CCNC (0.43) | HTR1DHTR1BHTR1ADRD2 | |
| SCHEMBL5311677 | 0.77 | JAK2 (0.55) | HTR1DHTR1BHTR1FHTR1A | |
| SCHEMBL5308040 | 0.77 | HTR1D (0.53) | HTR1DHTR1BHTR1FHTR1ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841427-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | Pozen, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | POZEN INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006081127-A2 | COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID | POZEN INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-0978514-B1 | Indazole derivatives as 5-HT1F agonists | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6133290-A | 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000006173-A1 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0978514-A1 | Indazole derivatives as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | HTR1F, HTR1A, HTR1E | HTR1D 13/4885HTR1B 7/4885HTR1F 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.